Recent Finacing
Recent Raise
Cortexyme is a South San Francisco clinical-stage pharmaceutical company developing orally administered bacterial protease inhibitors (lead COR388) and diagnostics targeting a pathogen linked to Alzheimer’s and other neurodegenerative diseases.
